Splenic irradiation prior to allogeneic transplant conditioning in myelofibrosis: A pilot experience.

[1]  A. Tefferi.  Primary myelofibrosis: 2023 update on diagnosis, risk‐stratification, and management , 2023, American journal of hematology.

[2]  T. Barbui,et al.  Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT. , 2022, The Lancet. Haematology.

[3]  A. El-Jawahri,et al.  Splenic irradiation prior to allogeneic hematopoietic cell transplantation for patients with myelofibrosis , 2022, Bone Marrow Transplantation.

[4]  M. Loh,et al.  International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data. , 2022, Blood.

[5]  P. Hari,et al.  Pretransplant Splenic Irradiation in Patients With Myeloproliferative Neoplasms , 2022, Advances in radiation oncology.

[6]  F. Farina,et al.  Addition of a Single Low Dose of Anti T-Lymphocyte Globulin to Post-Transplant Cyclophosphamide after Allogeneic Hematopoietic Stem Cell Transplant: A Pilot Study , 2022, Journal of clinical medicine.

[7]  F. Farina,et al.  Post-Transplant Cyclophosphamide and Sirolimus based Graft-versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant. , 2021, Transplantation and cellular therapy.

[8]  N. Kröger,et al.  Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT , 2021, Leukemia.

[9]  N. Kröger,et al.  Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend “when and for whom” in 2021? , 2021, Haematologica.

[10]  N. Kröger,et al.  Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT) , 2020, American journal of hematology.

[11]  I. Yakoub-Agha,et al.  European wide survey on allogeneic haematopoietic cell transplantation practice for myelofibrosis on behalf of the EBMT chronic malignancies working party. , 2020, Current research in translational medicine.

[12]  M. Cazzola,et al.  MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  N. Mukhopadhyay,et al.  Low-dose splenic irradiation prior to hematopoietic cell transplantation in hypersplenic patients with myelofibrosis , 2017, Leukemia & lymphoma.

[14]  M. Marcatti,et al.  Treosulfan based reduced toxicity conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosis , 2016, Hematological oncology.

[15]  T. Barbui,et al.  Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis , 2016, Leukemia.

[16]  G. Barosi,et al.  Improved Outcome of Alternative Donor Transplantations in Patients with Myelofibrosis: From Unrelated to Haploidentical Family Donors. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[17]  M. Sorror.  How I assess comorbidities before hematopoietic cell transplantation. , 2013, Blood.

[18]  M. Cazzola,et al.  A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). , 2010, Blood.

[19]  T Giorgino,et al.  A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis , 2017, Leukemia.